{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:50:33Z","timestamp":1761947433466},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T00:00:00Z","timestamp":1186704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2007,10,2]]},"DOI":"10.1007\/s00198-007-0439-4","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T17:10:58Z","timestamp":1186679458000},"page":"1439-1450","source":"Crossref","is-referenced-by-count":90,"title":["Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club"],"prefix":"10.1007","volume":"18","author":[{"given":"J. J.","family":"Body","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Boutsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,10]]},"reference":[{"key":"439_CR1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","volume":"18","author":"J Pfeilschifter","year":"2002","unstructured":"Pfeilschifter J, Diel IJ (2002) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570\u20131593","journal-title":"J Clin Oncol"},{"key":"439_CR2","first-page":"651","volume":"19","author":"AO Hoff","year":"2005","unstructured":"Hoff AO, Gagel RF (2005) Osteoporosis in breast and prostate cancer survivors. Oncology 19:651\u2013658","journal-title":"Oncology"},{"key":"439_CR3","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","volume":"103","author":"C Cooper","year":"1997","unstructured":"Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S\u201317S","journal-title":"Am J Med"},{"key":"439_CR4","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"439_CR5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","volume":"61","author":"PF Bruning","year":"1990","unstructured":"Bruning PF, Pit MJ, de Jong-Bakker M et al (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308\u2013310","journal-title":"Br J Cancer"},{"key":"439_CR6","first-page":"527","volume":"4","author":"AU Buzdar","year":"1998","unstructured":"Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4:527\u2013534","journal-title":"Clin Cancer Res"},{"key":"439_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1096-9098(199702)64:2<167::AID-JSO16>3.0.CO;2-3","volume":"64","author":"TJ Garrett","year":"1997","unstructured":"Garrett TJ, Vahdat LT, Kinne DW (1997) Systemic adjuvant therapy of breast cancer. J Surg Oncol 64:167\u2013172","journal-title":"J Surg Oncol"},{"key":"439_CR8","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","volume":"20","author":"W Jonat","year":"2002","unstructured":"Jonat W, Kaufmann M, Sauerbrei W et al (2002) Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628\u20134635","journal-title":"J Clin Oncol"},{"key":"439_CR9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","volume":"14","author":"I Fogelman","year":"2003","unstructured":"Fogelman I, Blake GM, Blamey R et al (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2\u00a0years of goserelin or 6\u00a0months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14:1001\u20131006","journal-title":"Osteoporos Int"},{"key":"439_CR10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852\u2013856","journal-title":"N Engl J Med"},{"key":"439_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"key":"439_CR12","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1200\/JCO.2002.06.020","volume":"20","author":"EP Winer","year":"2002","unstructured":"Winer EP, Hudis C, Burstein HJ, Chlebowski RT et al (2002) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 20:3317\u20133327","journal-title":"J Clin Oncol"},{"key":"439_CR13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629","journal-title":"J Clin Oncol"},{"key":"439_CR14","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"48","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 48:2431\u20132442","journal-title":"N Engl J Med"},{"key":"439_CR15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"439_CR16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ejca.2005.10.028","volume":"42","author":"EV McCloskey","year":"2006","unstructured":"McCloskey EV (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044\u20131051","journal-title":"Eur J Cancer"},{"key":"439_CR17","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-04-0438","volume":"10","author":"PE Goss","year":"2004","unstructured":"Goss PE, Qi S, Cheung AM, Hu H et al (2004) Effects of the F(7)steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 10:5717\u20135723","journal-title":"Clin Cancer Res"},{"issue":"14S","key":"439_CR18","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1200\/jco.2004.22.14_suppl.8038","volume":"22","author":"M Subar","year":"2004","unstructured":"Subar M, Goss PE, Thomsen T et al (2004) Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. J Clin Oncol 22(14S):8038","journal-title":"J Clin Oncol"},{"key":"439_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","volume":"17","author":"HM Heshmati","year":"2002","unstructured":"Heshmati HM, Khosla S, Robins SP et al (2002) Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172\u2013178","journal-title":"J Bone Miner Res"},{"issue":"18S","key":"439_CR20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/jco.2006.24.18_suppl.555","volume":"24","author":"E McCloskey","year":"2006","unstructured":"McCloskey E, Hannon R, Lakner G et al (2006) The letrozole (L), exemestane (E) and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J Clin Oncol 24(18S):555","journal-title":"J Clin Oncol"},{"key":"439_CR21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J et al (2006) On behalf of the ATAC Trialists\u2019 Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) Trial (18233230). J Bone Miner Res 21:1215\u20131223","journal-title":"J Bone Miner Res"},{"key":"439_CR22","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","volume":"42","author":"J Geisler","year":"2006","unstructured":"Geisler J, Lonning PE, Krag LE et al (2006) Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized placebo-controlled study. Eur J Cancer 42:2968\u20132975","journal-title":"Eur J Cancer"},{"key":"439_CR23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-1): a randomiser prevention trial. Lancet 360:817\u2013824","journal-title":"Lancet"},{"key":"439_CR24","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652\u20131662","journal-title":"J Natl Cancer Inst"},{"key":"439_CR25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J et al (2003) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists\u2019 Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802\u20131810","journal-title":"Cancer"},{"key":"439_CR26","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Thurlimann B, Keshaviah A, Coates AS et al (2005) Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757","journal-title":"N Engl J Med"},{"key":"439_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M et al (2005) ATAC Trialists\u2019 Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362","journal-title":"Lancet"},{"key":"439_CR28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"439_CR29","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA-17. J Clin Oncol 24:3629\u20133635","journal-title":"J Clin Oncol"},{"key":"439_CR30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"key":"439_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2\u00a0years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455\u2013462","journal-title":"Lancet"},{"key":"439_CR32","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","volume":"23","author":"PE Lonning","year":"2005","unstructured":"Lonning PE, Geisler J, Krag LE et al (2005) Effects of exemestane administered for 2\u00a0years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126\u20135137","journal-title":"J Clin Oncol"},{"key":"439_CR33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CBC.2006.n.021","volume":"7","author":"BA Mincey","year":"2006","unstructured":"Mincey BA, Duh MS, Thopmas SK, et al (2006) Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clinical Breast Cancer 7:127\u2013132","journal-title":"Clinical Breast Cancer"},{"key":"439_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S8756-3282(02)00787-1","volume":"31","author":"AR Martin","year":"2002","unstructured":"Martin AR, Sornay-Rendu E, Chandler JM et al (2002) The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 31:32\u201336","journal-title":"Bone"},{"key":"439_CR35","first-page":"32","volume":"17","author":"SS Padalecki","year":"2003","unstructured":"Padalecki SS, Carreon M, Grubbs B et al (2003) Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid. Oncology 17 (Suppl):32","journal-title":"Oncology"},{"key":"439_CR36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00520-005-0913-5","volume":"14","author":"JJ Body","year":"2006","unstructured":"Body JJ (2006) Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14:408\u2013418","journal-title":"Support Care Cancer"},{"key":"439_CR37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ten.0000123564.40707.84","volume":"14","author":"CA Morris","year":"2004","unstructured":"Morris CA, Cheng H, Cabral D et al (2004) Predictors of screening and treatment of osteoporosis: a structural review of the literature. Endocrinologist 14:70\u201375","journal-title":"Endocrinologist"},{"key":"439_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/JCD:7:1:37","volume":"7","author":"Writing Group for the ISCD, Position Development Conference","year":"2004","unstructured":"Writing Group for the ISCD, Position Development Conference (2004) Indications and reporting for dual-energy X-ray absorptiometry. J Clin Densitom 7:37\u201344","journal-title":"J Clin Densitom"},{"key":"439_CR39","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u201357 Erratum in: (2004) J Clin Oncol 22:1351"},{"key":"439_CR40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341\u20131347","journal-title":"J Clin Oncol"},{"key":"439_CR41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955\u2013962","journal-title":"J Clin Oncol"},{"key":"439_CR42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"M Gnant","year":"2007","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820\u2013828","journal-title":"J Clin Oncol"},{"key":"439_CR43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829\u2013836","journal-title":"J Clin Oncol"},{"key":"439_CR44","first-page":"499","volume":"12","author":"JW Moul","year":"1998","unstructured":"Moul JW (1998) Contemporary hormonal management of advanced prostate cancer. Oncology 12:499\u2013505","journal-title":"Oncology"},{"key":"439_CR45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0889-8588(05)70364-6","volume":"10","author":"M Robson","year":"1996","unstructured":"Robson M, Dawson N (1996) How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 10:727\u2013747","journal-title":"Hematol Oncol Clin North Am"},{"key":"439_CR46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","volume":"338","author":"R Eastell","year":"1998","unstructured":"Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736\u2013746","journal-title":"N Engl J Med"},{"key":"439_CR47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","volume":"31","author":"CS Higano","year":"2004","unstructured":"Higano CS (2004) Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 31:331\u2013352","journal-title":"Urol Clin North Am"},{"key":"439_CR48","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"JF Maillefert","year":"1999","unstructured":"Maillefert JF, Sibilia J, Michel F et al (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219\u20131222","journal-title":"J Urol"},{"key":"439_CR49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","volume":"57","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Eriksson A, Stege R et al (1995) Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57:97\u201399","journal-title":"Calcif Tissue Int"},{"key":"439_CR50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW, Dunn SR, Ferguson DW et al (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181\u2013186","journal-title":"J Urol"},{"key":"439_CR51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","volume":"157","author":"HW Daniell","year":"1997","unstructured":"Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439\u2013444","journal-title":"J Urol"},{"key":"439_CR52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","volume":"79","author":"MF Townsend","year":"1997","unstructured":"Townsend MF, Sanders WH, Northway RO et al (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545\u2013550","journal-title":"Cancer"},{"key":"439_CR53","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","volume":"166","author":"MG Oefelein","year":"2001","unstructured":"Oefelein MG, Ricchuiti V, Conrad W et al (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166:1724\u20131728","journal-title":"J Urol"},{"key":"439_CR54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","volume":"175","author":"MR Smith","year":"2006","unstructured":"Smith MR, Boyce SP, Moyneur E et al (2006) Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136\u2013139","journal-title":"J Urol"},{"key":"439_CR55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"439_CR56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599\u2013603","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR57","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa Van","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000","journal-title":"J Bone Miner Res"},{"key":"439_CR58","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1210\/jc.2002-021691","volume":"88","author":"I Pottelbergh Van","year":"2003","unstructured":"Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polyorphism are determinants of bone mineral density changes in men over 70\u00a0years of age. J Clin Endocrinol Metab 88:3075\u20133081","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR59","first-page":"219","volume":"85","author":"E Barrett-Connor","year":"2000","unstructured":"Barrett-Connor E, Mueller JE, von Muhlen DG et al (2000) Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:219\u2013223","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199808273390905","volume":"339","author":"JP Bilezikian","year":"1998","unstructured":"Bilezikian JP, Morishima A, Bell J et al (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599\u2013603","journal-title":"N Engl J Med"},{"key":"439_CR61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","volume":"41","author":"J Verhelst","year":"1994","unstructured":"Verhelst J, Denis L, Van Vliet P et al (1994) Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol 41:525\u2013530","journal-title":"Clin Endocrinol"},{"key":"439_CR62","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR, Goode M, Zietman AL et al (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22:2546\u20132553","journal-title":"J Clin Oncol"},{"key":"439_CR63","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"TH Diamond","year":"2004","unstructured":"Diamond TH, Higano CS, Smith MR et al (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892\u2013899","journal-title":"Cancer"},{"key":"439_CR64","first-page":"3431","volume":"84","author":"JP Bilezikian","year":"1999","unstructured":"Bilezikian JP (1999) Osteoporosis in men. J Clin Endocrinol Metab 84:3431\u20133434","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR65","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841\u20133846","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR66","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1210\/jc.2002-020539","volume":"87","author":"P Taxel","year":"2002","unstructured":"Taxel P, Fall PM, Albertsen PC et al (2002) The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 87:4907\u20134913","journal-title":"J Clin Endocrinol Metab"},{"key":"439_CR67","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948\u2013955","journal-title":"N Engl J Med"},{"key":"439_CR68","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","volume":"92","author":"TH Diamond","year":"2001","unstructured":"Diamond TH, Winters J, Smith A et al (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92:1444\u20131450","journal-title":"Cancer"},{"key":"439_CR69","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008\u20132012","journal-title":"J Urol"},{"key":"439_CR70","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gondotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038\u20131042","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"439_CR71","first-page":"S93","volume":"20","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Wagner JM, Nelson JB et al (2005) Alendronate prevents bone loss in men on androgen deprivation therapy for prostate cancer. J Bone Miner Res 20 (Suppl 1):S93 (Abstr F381)","journal-title":"J Bone Miner Res"},{"key":"439_CR72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jocd.2006.07.005","volume":"9","author":"JM Bruder","year":"2006","unstructured":"Bruder JM, Ma JZ, Wing M et al (2006) Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 9:431\u2013437","journal-title":"J Clin Densitom"},{"issue":"Suppl 11","key":"439_CR73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/sonc.2001.25426","volume":"28","author":"JJ Body","year":"2001","unstructured":"Body JJ (2001) Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28 (Suppl 11):49\u201353","journal-title":"Semin Oncol"},{"key":"439_CR74","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676\u20131679","journal-title":"N Engl J Med"},{"key":"439_CR75","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"439_CR76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR (2006) Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753\u2013761","journal-title":"Ann Intern Med"},{"key":"439_CR77","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","volume":"355","author":"JP Bilezikian","year":"2006","unstructured":"Bilezikian JP (2006) Osteonecrosis of the jaw - Do bisphosphonates pose a risk? N Engl J Med 355:2278\u20132281","journal-title":"N Engl J Med"},{"key":"439_CR78","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"439_CR79","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00000421-200308001-00005","volume":"26","author":"PE Goss","year":"2003","unstructured":"Goss PE (2003) Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 26:S27\u2013S33","journal-title":"Am J Clin Oncol"},{"key":"439_CR80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589","journal-title":"Osteoporos Int"},{"key":"439_CR81","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"TA Guise","year":"2006","unstructured":"Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. The Oncologist 11:1121\u20131131","journal-title":"The Oncologist"},{"key":"439_CR82","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","volume":"24","author":"AJ Chien","year":"2006","unstructured":"Chien AJ, Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305\u20135312","journal-title":"J Clin Oncol"},{"key":"439_CR83","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR et al (2003) MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"439_CR84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14656566.4.4.567","volume":"4","author":"JJ Body","year":"2003","unstructured":"Body JJ (2003) Zoledronic acid: an advance in tumour bone disease and a new hope for osteoporosis. Expert Opin Pharmacother 4:567\u2013580","journal-title":"Expert Opin Pharmacother"},{"issue":"6 Pt 2","key":"439_CR85","first-page":"S50","volume":"176","author":"S Srinivas","year":"2006","unstructured":"Srinivas S, Colocci N (2006) Bone related events in high risk prostate cancer. J Urol 176 (6 Pt 2):S50\u2013S54","journal-title":"J Urol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-007-0439-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0439-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T19:16:08Z","timestamp":1587842168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-007-0439-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,10]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,10,2]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s00198-007-0439-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,10]]}}}